Clinical Trial Update: A Study to Assess Deucravacitinib Post-marketing Surveillance in Participants With Psoriasis in Japan

View source ↗

Summary

A post-marketing surveillance study evaluating Deucravacitinib for psoriasis in Japan has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Sotyktu (Deucravacitinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Psoriasis | Status: COMPLETED